Vaccination of multiple myeloma: Current strategies and future prospects
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2015-06-18 / Crit. Rev. Oncol. Hematol. 2015 Nov;96(2):339-54Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).
/in Dendritic Cells, Glioblastoma, International Publications /von 2015-06-17 / J Clin Oncol 33, 2015 (suppl; abstr e13030)Brain Tumor Immunotherapy: What have We Learned so Far?
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-06-17 / Front Oncol 2015;5:98IOZK Fallstudie zum Langzeitüberleben einer Patientin mit Brustkrebs
/in IOZK Meldungen, IOZK Veröffentlichungen /von IOZKRe-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-06-13 / J. Neurooncol. 2015 Sep;124(2):325-32Beitrag von Prof. Dr. Schirrmacher in der Wiener medizinischen Wochenschrift „Skriptum“
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKRecombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
/in International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2015-06-11 / Viruses 2015 Jun;7(6):2980-98Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy
/in Breast Cancer, Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2015-06-02 / Front Immunol 2015;6:271Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107.
/in Dendritic Cells, Glioblastoma, International Publications /von 2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr 2036)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution